SMC accepts Boehringer/Lilly’s Jardiance for CKD within NHS Scotland
The serious, progressive kidney disease affects nearly 850 million people worldwide
Read More
Tag: empagliflozin
FDA dismisses Jardiance for type I diabetes
The decision follows an FDA panel vote last November recommending against the approval of the drug.
Read More
Jardiance bags FDA Fast Track designation
The decision follows a Jardiance Fast Track designation which was granted by the FDA in July 2019 for the risk of cardiovascular death.
Read More
Oxford Uni, Boehringer, Lilly link to test Jardiance in kidney disease
Boehringer Ingelheim and Eli Lilly are linking with Oxford University to assess the effect of SGLT2 inhibitor Jardiance on kidney disease and cardiovascular death.
Read More
BI, Lilly expand Jardiance programme in heart failure
Boehringer Ingelheim and Eli Lilly are expanding their clinical trial programme for Jardiance in chronic heart failure (CHF) with two new Phase III studies.
Read More
US OKs CV death risk reduction data for empagliflozin
The US Food and Drug Administration has given its consent for the inclusion of clinical trial data showing a reduction in the risk of death with three type II diabetes medicines from the empagliflozin family.
Read More
FDA nod for Boehringer/Lilly’s once-daily diabetes combo
US regulators have cleared the use of a once-daily formulation of Boehringer Ingelheim and Eli Lilly’s diabetes drug Synjardy.
Read More
FDA allows cardiovascular death reduction claim for Jardiance
In a huge boon for Lilly and Boehringer Ingelheim, US regulators have expanded the scope of diabetes drug Jardiance to include a reduction in the risk of cardiovascular death patients with type II forms of the condition and cardiovascular disease.
Read More
US regulators expand use of Boehringer/Lilly’s diabetes drug
US regulators have expanded the scope of Boehringer Ingelheim and Eli Lilly’s Synjardy to include treatment-naïve adults with type II diabetes.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
